Dr. Chow Maneval will serve on the executive leadership team and, together with chief medical officer Pratik Multani, MD, lead clinical development for ORIC.

“ORIC continues to attract top talent to its leadership team with our newest addition, Edna Chow Maneval. Edna has a multi-decade track record of leadership and success in oncology drug development, including multiple new drug applications during her time at Ignyta, Aragon, and Pfizer,” said Jacob Chacko, MD, chief executive officer of ORIC. “We are pleased that she is joining ORIC at this critical inflection point as we begin clinical studies of ORIC-101 in patients with solid tumors and continue to progress our pipeline.”

“I am excited to join ORIC and work with its accomplished founders and scientists,” said Dr. Chow Maneval. “ORIC is at the forefront of work to address the challenge of treatment resistance in advanced cancers, beginning with Phase 1b studies of the glucocorticoid receptor antagonist in multiple patient populations and continuing with the rest of the pipeline.”